Why the study?
Do serotonin inhibitors affect initial microvessel hemostasis and platelet aggregation in vivo?
Do serotonin inhibitors affect initial microvessel hemostasis and platelet aggregation in vivo?
Serotonin inhibition does not significantly alter initial microvessel hemostasis or platelet activity in vivo, suggesting serotonin plays a minor role in these processes.
Animal data suggest limited serotonin role in microvessel hemostasis; leaves open relevance to human thrombosis.
The role of serotonin (5-HT) in initial microvascular hemostasis is not fully understood. This study was made to evaluate the effect on hemostatic plug formation and laser-induced arteriolar microembolism of different substances which counteract the effect of 5-HT. Hemostatic plug formation time and stability was measured in the rabbit mesenteric microcirculation and laser-induced embolism in the rabbit ear chamber. Ketanserine, a selective 5-HT2-receptor blocker shortened arteriolar hemostatic plug formation time. Dihydroergotamine, an unselective blocker (with 5-HT-and alpha-adrenergic receptor affinity) increased venular hemostatic plug formation time and also decreased the hemostatic plug stability. Laser-induced platelet embolism was unaltered after both ketanserine and dihydroergotamine administration. The magnitude of these changes seems to exclude an important effect of 5-HT in initial microvessel hemostasis or on platelet activity.
No takes yet. Share an insight, caveat, or question.
Bergqvist et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: